These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19334714)

  • 1. Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.
    Mandal PK; Limbrick D; Coleman DR; Dyer GA; Ren Z; Birtwistle JS; Xiong C; Chen X; Briggs JM; McMurray JS
    J Med Chem; 2009 Apr; 52(8):2429-42. PubMed ID: 19334714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
    Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
    J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3.
    Mandal PK; Ren Z; Chen X; Xiong C; McMurray JS
    J Med Chem; 2009 Oct; 52(19):6126-41. PubMed ID: 19728728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the binding of high affinity phosphopeptides to Stat3.
    McMurray JS
    Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).
    Mandal PK; Ren Z; Chen X; Kaluarachchi K; Liao WS; McMurray JS
    Int J Pept Res Ther; 2013 Mar; 19(1):3-12. PubMed ID: 24707243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
    Nam NH; Ye G; Sun G; Parang K
    J Med Chem; 2004 Jun; 47(12):3131-41. PubMed ID: 15163193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.
    Mandal PK; Gao F; Lu Z; Ren Z; Ramesh R; Birtwistle JS; Kaluarachchi KK; Chen X; Bast RC; Liao WS; McMurray JS
    J Med Chem; 2011 May; 54(10):3549-63. PubMed ID: 21486047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On modeling peptidomimetics in complex with the SH2 domain of Stat3.
    Dhanik A; McMurray JS; Kavraki L
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3229-32. PubMed ID: 22255027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding.
    Davidson JP; Lubman O; Rose T; Waksman G; Martin SF
    J Am Chem Soc; 2002 Jan; 124(2):205-15. PubMed ID: 11782172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.
    Schoepfer J; Gay B; Caravatti G; Garcia-Echeverria C; Fretz H; Rahuel J; Furet P
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2865-70. PubMed ID: 9873638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
    Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
    Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
    Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
    Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.
    Shahani VM; Yue P; Fletcher S; Sharmeen S; Sukhai MA; Luu DP; Zhang X; Sun H; Zhao W; Schimmer AD; Turkson J; Gunning PT
    Bioorg Med Chem; 2011 Mar; 19(5):1823-38. PubMed ID: 21216604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3.
    Wiederkehr-Adam M; Ernst P; Müller K; Bieck E; Gombert FO; Ottl J; Graff P; Grossmüller F; Heim MH
    J Biol Chem; 2003 May; 278(18):16117-28. PubMed ID: 12591923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
    Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A
    Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
    Furtek SL; Matheson CJ; Backos DS; Reigan P
    Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
    Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
    J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding modes of peptidomimetics designed to inhibit STAT3.
    Dhanik A; McMurray JS; Kavraki LE
    PLoS One; 2012; 7(12):e51603. PubMed ID: 23251591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
    Page BD; Fletcher S; Yue P; Li Z; Zhang X; Sharmeen S; Datti A; Wrana JL; Trudel S; Schimmer AD; Turkson J; Gunning PT
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5605-9. PubMed ID: 21788134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.